Multiple Myeloma: Enhancing Communication With Your Patient For Optimal Outcomes

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Framework for Discussing Multiple Myeloma Treatment With Patients

Team-Based Approach

Practice Pearls for Patient Communication

Key Communication Points in Initial And Maintenance Therapy for Multiple Myeloma

Be Prepared for Complex Questions

Tools for Optimizing Adherence

Selecting Treatment for Relapsed Multiple Myeloma is Complex

Implementing Shared Decision-Making in Multiple Myeloma Treatment

Encouraging Communication During Therapy

Key Takeaways

Abbreviations

Abbreviations (cont)